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Background
PRO 2000 is a polyanionic compound under develop-
ment as a topical antimicrobial gel for the prevention of
HIV-1 transmission. PRO 2000 is a synthetic naphtha-
lene polymer which is documented to bind to HIV-1
gp120 and interferes with virus binding to CD4
+ T cells.
Peculiar is that PRO 2000 appears to be more active
(~10-fold) in inhibiting X4 viruses (IC50:1 . 9μg/ml)
compared to R5 viruses (IC50: 20.8 μg/ml). Therefore,
we investigated interactions of PRO 2000 with cellular
HIV (co)-receptors.
Methods
Peripheral blood mononuclear cells (PBMCs) were incu-
bated with PRO 2000 and flow cytometric assays
performed using various fluorescent mAbs. Chemokine-
induced signaling experiments were performed by
FLIPR. Chemotaxis experiments were performed in
5-μm pore transwell filter membranes. CXCL12
AF647
binding was monitored by flow cytometry. The Bio-Plex
human cytokine 27-plex assay system was used for the
detection of cytokines/chemokines in PBMCs.
Results
PRO 2000 dose-dependently interfered with the binding
of several anti-CD4 mAbs (clone OKT4, Leu3a, SK3)
and anti-CXCR4 (clone 2B11 and 12G5) in PBMCs,
whereas minor or no effects were observed on DC-
SIGN and CCR5. The compound inhibited the
CXCL12-induced signal transduction (IC50:1 9 . 9μg/ml),
CXCR4 internalization (IC50:9 . 5μg/ml) and chemotaxis
in PBMCs (IC50:6 . 7μg/ml). It inhibited CXCL12
AF647
binding to T cells with an IC50 of 2.2 μg/ml. PRO 2000
did not induce signaling by itself. These CXCR4 antago-
nistic properties of PRO 2000 are potential additional
mechanism of action that could explain the observation
that PRO 2000 is more active against X4 viruses. In
addition, we also examined the cellular activation poten-
tial and cytokines profile of PRO 2000 in PBMCs. PRO
2000 had minor effects on the induction of the activa-
tion markers CD25, CD69 and HLA-DR on T cells, but
it did enhance the production of a small number of
cytokines/chemokines, and most dramatically the pro-
duction (~30-fold) of the specific CCR5 ligand MIP-1b.
Discussion
Thus, PRO 2000 is not just a pure gp120 binding inhibi-
tor to CD4
+ T cells, but also interacts with CD4 and
CXCR4 and can induce selective chemokines with
potential anti-viral activity.
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